Novartis Trial Failure Impacts Amgen and Lp(a) Drug Class Stock Performance
Novartis has recently reported a significant setback for the entire Lp(a) drug class following the failure of its experimental heart drug, pelacarsen, to demonstrate a reduction in cardiovascular risk in a late-stage trial. This news has had a pronounced impact on Amgen, which saw its stock price drop by 10% to $394.38, despite announcing positive Phase 3 trial results for its own drug on the same day. The market's reaction underscores how competitor risks can heavily influence stock valuations in the biotech sector, particularly when it comes to treatments for cholesterol management.
The failed trial involved 8,323 patients and aimed to assess the efficacy of pelacarsen in reducing cardiovascular events, including cardiovascular death and non-fatal heart attacks. Although the trial succeeded in lowering Lp(a) levels, it did not meet its primary endpoint, raising questions about the validity of the Lp(a) hypothesis itself. Analysts from Citi have indicated that further data is necessary to determine whether the failure stemmed from the drug's mechanism, the design of the trial, or the underlying premise that lowering Lp(a) can effectively reduce cardiovascular risk.
Amgen, which has invested significantly in its Lp(a)-lowering therapies, has been particularly affected by this news. Its stock decline is notable given that it holds a substantial position in the Dow Jones Industrial Average, and this drop may also influence the index's performance. Meanwhile, Eli Lilly also experienced a modest decline of 2% in its stock, reflecting concerns about its own Lp(a) program in light of Novartis's failure.
Despite the negative market reaction, Amgen did announce that its Phase 3 DeLLphi-305 study for its drug IMDELLTRA had met its primary endpoint, showing a statistically significant improvement in overall survival for patients with extensive stage small cell lung cancer. This positive outcome contrasts sharply with the news from Novartis and illustrates the complexities of the biotech market, where one company's success can be overshadowed by another's failure.
Amgen's cholesterol treatment portfolio remains significant, with its PCSK9 inhibitor, Repatha, generating substantial revenue growth. The company is also advancing its Lp(a) therapy, Olpasiran, which is currently undergoing a cardiovascular outcomes trial. The failure of Novartis's pelacarsen trial has led to a reevaluation of the entire Lp(a) drug class, and investors are now more cautious about the prospects of Amgen's pipeline.
As the market continues to react to these developments, analysts suggest that investors should moderate their exposure to large-cap pharmaceutical stocks until further clarity emerges from ongoing trials and presentations. The distinction between a failed drug and a failed idea will be crucial as the industry awaits additional data that could reshape the narrative surrounding Lp(a) therapies.




